BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 33714200)

  • 1. A novel panel based on immune infiltration and tumor mutational burden for prognostic prediction in hepatocellular carcinoma.
    Xie C; Wu H; Pan T; Zheng X; Yang X; Zhang G; Lian Y; Lin J; Peng L
    Aging (Albany NY); 2021 Mar; 13(6):8563-8587. PubMed ID: 33714200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data.
    Liu S; Tang Q; Huang J; Zhan M; Zhao W; Yang X; Li Y; Qiu L; Zhang F; Lu L; He X
    Aging (Albany NY); 2021 Apr; 13(8):11257-11280. PubMed ID: 33820866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of TMB and the relationship between TMB and immune infiltration in head and neck squamous cell carcinoma: A gene expression-based study.
    Zhang L; Li B; Peng Y; Wu F; Li Q; Lin Z; Xie S; Xiao L; Lin X; Ou Z; Cai T; Rong H; Fan S; Li J
    Oral Oncol; 2020 Nov; 110():104943. PubMed ID: 32919362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor Mutation Burden Predicts Relapse in Papillary Thyroid Carcinoma With Changes in Genes and Immune Microenvironment.
    Guo M; Chen Z; Li Y; Li S; Shen F; Gan X; Feng J; Cai W; Liu Q; Xu B
    Front Endocrinol (Lausanne); 2021; 12():674616. PubMed ID: 34248843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39
    Liu T; Tan J; Wu M; Fan W; Wei J; Zhu B; Guo J; Wang S; Zhou P; Zhang H; Shi L; Li J
    Gut; 2021 Oct; 70(10):1965-1977. PubMed ID: 33262196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive Pan-Cancer Genomic Analysis Reveals PHF19 as a Carcinogenic Indicator Related to Immune Infiltration and Prognosis of Hepatocellular Carcinoma.
    Zhu ZY; Tang N; Wang MF; Zhou JC; Wang JL; Ren HZ; Shi XL
    Front Immunol; 2021; 12():781087. PubMed ID: 35069553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploration of gene expression profiles and immune microenvironment between high and low tumor mutation burden groups in prostate cancer.
    Luo C; Chen J; Chen L
    Int Immunopharmacol; 2020 Sep; 86():106709. PubMed ID: 32593155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression and immune infiltration in melanoma patients with different mutation burden.
    Wang L; Chen F; Liu R; Shi L; Zhao G; Yan Z
    BMC Cancer; 2021 Apr; 21(1):379. PubMed ID: 33836680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma.
    Dong LQ; Peng LH; Ma LJ; Liu DB; Zhang S; Luo SZ; Rao JH; Zhu HW; Yang SX; Xi SJ; Chen M; Xie FF; Li FQ; Li WH; Ye C; Lin LY; Wang YJ; Wang XY; Gao DM; Zhou H; Yang HM; Wang J; Zhu SD; Wang XD; Cao Y; Zhou J; Fan J; Wu K; Gao Q
    J Hepatol; 2020 May; 72(5):896-908. PubMed ID: 31887370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of LRP1B mutation-associated prognostic model for hepatocellular carcinoma.
    Xu J; Shen X; Zhang B; Su R; Cui M; Yan L; Cao Y
    Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34386813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive analysis of tumour mutation burden and the immune microenvironment in hepatocellular carcinoma.
    Xie F; Bai Y; Yang X; Long J; Mao J; Lin J; Wang D; Song Y; Xun Z; Huang H; Yang X; Zhang L; Mao Y; Sang X; Zhao H
    Int Immunopharmacol; 2020 Dec; 89(Pt A):107135. PubMed ID: 33189609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a seven-gene signature predicting clinical outcome of liver cancer based on tumor mutational burden.
    Cui Y; Jiang N
    Hum Cell; 2022 Jul; 35(4):1192-1206. PubMed ID: 35622212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EOGT Correlated With Immune Infiltration: A Candidate Prognostic Biomarker for Hepatocellular Carcinoma.
    Shu Y; He L; Gao M; Xiao F; Yang J; Wang S; Wei H; Zhang F; Wei H
    Front Immunol; 2021; 12():780509. PubMed ID: 35069551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive analysis of genomic and immunological profiles in Chinese and Western hepatocellular carcinoma populations.
    Li W; Wu H; Xu X; Zhang Y
    Aging (Albany NY); 2021 Apr; 13(8):11564-11594. PubMed ID: 33867349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of CCR1/5/7 in hepatocellular carcinoma: a study on prognostic evaluation, molecular subtyping, and association with immune infiltration.
    Huang H; Lan C; Wei Y; Nong J; Liao X; Ye X; Deng G; Peng T; Zhou X
    Aging (Albany NY); 2024 Mar; 16(7):6229-6261. PubMed ID: 38552222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EPDR1 correlates with immune cell infiltration in hepatocellular carcinoma and can be used as a prognostic biomarker.
    Chen R; Zhang Y
    J Cell Mol Med; 2020 Oct; 24(20):12107-12118. PubMed ID: 32935479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.
    Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L
    Front Immunol; 2022; 13():943389. PubMed ID: 36003381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Papillary thyroid carcinoma with a high tumor mutation burden has a poor prognosis.
    Xie Z; Li X; Lun Y; He Y; Wu S; Wang S; Sun J; He Y; Xin S; Zhang J
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107090. PubMed ID: 33091816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation analysis of RDM1 gene with immune infiltration and clinical prognosis of hepatocellular carcinoma.
    Qiu C; Li Z; Cao W; Cai X; Ye L; Zhang C; Ma Y; Wang X; Yang Y
    Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34435618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of LOXL3-associating immune infiltration landscape and prognostic value in hepatocellular carcinoma.
    Wang N; Zhou X; Tang F; Wang X; Zhu X
    Virchows Arch; 2021 Dec; 479(6):1153-1165. PubMed ID: 34448895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.